Ozanimod - Celgene Corporation
Alternative Names: BMS-986374; Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl; ZEPOSIALatest Information Update: 27 Aug 2024
At a glance
- Originator The Scripps Research Institute
- Developer Bristol-Myers Squibb; Celgene Corporation; Receptos
- Class Amines; Anti-inflammatories; Antivirals; Benzene derivatives; Indenes; Nitriles; Oxadiazoles; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis; Ulcerative colitis
- Phase III Crohn's disease
- Phase II COVID 2019 infections
Most Recent Events
- 18 May 2024 Adverse events data from a phase III TRUE NORTH open-label extension trial in Ulcerative colitis presented at the Digestive Disease Week 2024 (DDW-2024)
- 18 May 2024 Efficacy data from the phase II STEPSTONE extension trial in Crohn's disease presented at Digestive Disease Week 2024 (DDW-2024)
- 10 May 2024 Celgene plans a phase III trial for Multiple Sclerosis (In-children, In-adolescents, Treatment-experienced) in the USA (PO) (NCT06408259)